A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

Heerspink, Hiddo J. L.Cherney, DavidPostmus, DouweStefánsson, Bergur V.Chertow, Glenn M.Dwyer, Jamie P.Greene, TomKosiborod, M. N.Langkilde, Anna-MariaMcMurray, John J.Correa-Rotter, RicardoRossing, PeterSjöström, C. DavidToto, Roberto D.Wheeler, David C.Nagy, Gergely György2025-01-092025-01-092022Kidney International. -101 : 1 (2022), p. 174-184. -Kidney Int. - 0085-2538. - 1523-17550085-25381523-1755https://hdl.handle.net/2437/384681A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney functionfolyóiratcikkopen access articlehttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM126505OrvostudományokKlinikai orvostudományokhttps://linkinghub.elsevier.com/retrieve/pii/S0085253821008656szerzőhttp://dx.doi.org/10.1016/j.kint.2021.09.0052025-01-0900075336380002185120341223